Jack Chang

Dr. Jack Chang

Midwestern University, Downers Grove, Illinois, USA
+1
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 June 2022 in Clinical Pharmacokinetics
Verified
Journal Article
Closed access
PDF file
GPGwendolyn M. Pais
Gwendolyn M. Pais
JCJack Chang
Jack Chang
EBErin F. Barreto
Erin F. Barreto
GSGideon Stitt
Gideon Stitt
KDKevin J. Downes
Kevin J. Downes
MSMarc Scheetz
Marc Scheetz

15 March 2022 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
JCJack Chang
Jack Chang
GPGwendolyn Pais
Gwendolyn Pais
KVKimberly Valdez
Kimberly Valdez
SMSylwia Marianski
Sylwia Marianski
EBErin F Barreto
Erin F Barreto
MSMarc Scheetz
Marc Scheetz
Clinical studies have reported additive nephrotoxicity associated with the combination of vancomycin (VAN) and piperacillin-tazobactam (TZP). This study assessed differences in glomerular filtration rate (GFR) and urinary biomarkers between rats receiving VAN and those receiving VAN + TZP.

2 November 2023 in Expert Review of Anti-infective Therapy
Verified
Journal Article
Closed access
JCJack Chang
Jack Chang
ATArdita Tasellari
Ardita Tasellari
Jamie WagnerJamie Wagner
Jamie Wagner
MSMarc Scheetz
Marc Scheetz
Methicillin-resistant Staphylococcus aureus (MRSA) remains an important pathogen in the hospital setting and causes significant morbidity and mortality each year. Since the initial discovery over 60 years ago, vancomycin has remained a first-line treatment for many different types of MRSA infections. However, significant concerns related to target attainment and nephrotoxicity have spurred efforts to develop more effective agents in the last two decades. Newer anti-MRSA antibiotics that have been approved since 2000 include linezolid, daptomycin, and ceftaroline. As clinical evidence has accumulated, these newer agents have become more frequently used, and some are now recommended as co-first line options (along with vancomycin) in clinical practice guidelines. For this review, a scoping review of the literature was conducted to support our findings and recommendations. Vancomycin remains an important standard of care for MRSA infections but is limited with respect to nephrotoxicity and rapid target attainment. Newer agents such as linezolid, daptomycin, and ceftaroline have specific indications for treating different types of MRSA infections; however, newer agents also have unique attributes which require consideration during therapy.

1 April 2022 in International Journal of Antimicrobial Agents
Verified
Journal Article
Closed access
GPGwendolyn M. Pais
Gwendolyn M. Pais
JCJack Chang
Jack Chang
JLJiajun Liu
Jiajun Liu
MSMarc Scheetz
Marc Scheetz

4 July 2017 in Clinical and Translational Science
Verified
Journal Article
Open access
PDF file
MJM D Joshi
M D Joshi
JOJn O'DOnnell
Jn O'DOnnell
NVN Venkatesan
N Venkatesan
JCJack Chang
Jack Chang
HNH Nguyen
H Nguyen
MSMarc Scheetz
Marc Scheetz
A translational need exists to understand and predict vancomycin‐induced kidney toxicity. We describe: (i) a vancomycin high‐performance liquid chromatography (HPLC) method for rat plasma and kidney tissue homogenate; (ii) a rat pharmacokinetic (PK) study to demonstrate utility; and (iii) a catheter retention study to enable future preclinical studies. Rat plasma and pup kidney tissue homogenate were analyzed via HPLC for vancomycin concentrations ranging from 3–75 and 15.1–75.5 μg/mL, respectively, using a Kinetex Biphenyl column and gradient elution of water with 0.1% formic acid: acetonitrile (70:30 v/v). Sprague‐Dawley rats (n = 10) receiving 150 mg/kg of vancomycin intraperitoneally had plasma sampled for PK. Finally, a catheter retention study was performed on polyurethane catheters to assess adsorption. Precision was 96.3% analyte recovery. A two‐compartment model fit the data well, facilitating PK exposure estimates. Finally, vancomycin was heterogeneously retained by polyurethane catheters.

Verified
Journal Article
Open access
PDF file
ELEleni Laou
Eleni Laou
Theodoros MavridisTheodoros Mavridis
Theodoros Mavridis
Nikolaos PapagiannakisNikolaos Papagiannakis
Nikolaos Papagiannakis
GPGwendolyn Pais
Gwendolyn Pais
ACAlberto Chighine
Alberto Chighine
Theodoros XanthosTheodoros Xanthos
Theodoros Xanthos
Background: several blood-based biomarkers have been proposed for predicting vancomycin-associated kidney injury (VIKI). However, no systematic analysis has compared their prognostic value. Objective: this systematic review and meta-analysis was designed to investigate the role of blood biomarkers and metabolomic profiling as diagnostic and prognostic predictors in pre-clinical studies of VIKI. Methods: a systematic search of PubMed was conducted for relevant articles from January 2000 to May 2022. Animal studies that administered vancomycin and studied VIKI were eligible for inclusion. Clinical studies, reviews, and non-English literature were excluded. The primary outcome was to investigate the relationship between the extent of VIKI as measured by blood biomarkers and metabolomic profiling. Risk of bias was assessed with the CAMARADES checklist the SYRCLE’s risk of bias tool. Standard meta-analysis methods (random-effects models) were used. Results: there were four studies for the same species, dosage, duration of vancomycin administration and measurement only for serum creatine and blood urea nitrogen in rats. A statistically significant increase was observed between serum creatinine in the vancomycin group compared to controls (pooled p = 0.037; Standardized Mean Difference: 2.93; 95% CI: 0.17 to 5.69; I2 = 92.11%). Serum BUN levels were not significantly different between control and vancomycin groups (pooled p = 0.11; SMD: 3.05; 95% CI: 0.69 to 6.8; I2 = 94.84%). We did not identify experimental studies using metabolomic analyses in animals with VIKI. Conclusions: a total of four studies in rodents only described outcomes of kidney injury as defined by blood biomarkers. Blood biomarkers represented included serum creatinine and BUN. Novel blood biomarkers have not been explored.